MONTREAL (CANADA) – May 20, 2021 – Inversago Pharma Inc., the peripheral CB1 blockade company, today announced that François Ravenelle, PhD, CEO and Founder, will be presenting at the Oppenheimer Rare & Orphan Disease Summit.
Details are as follows:
Date: Friday, May 21, 2021
Time: 2:55 pm ET
Format: 40-minute live virtual presentation
About the Summit
Oppenheimer Healthcare is dedicated to finding and highlighting opportunities in Rare & Orphan Disease to investors. On May 21, the virtual Rare & Orphan Disease Summit will feature 1on1 meetings with a select group of specialty pharma and biotech companies focused on developing therapies and treatments for some of these rare and orphan diseases. Investors will have the opportunity to meet with management teams to discuss in detail key therapeutic programs in development and recent corporate updates.
About Inversago Pharma
Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy. For more information, visit inversago.com.
– 30 –
Contact
François Ravenelle, PhD
Chief Executive Officer
Inversago Pharma inc.
info@inversago.com
